Ibrutinib (Imbruvica) for Waldenström's macroglobulinaemia

NIHR HSRIC
Record ID 32016000333
English
Authors' objectives: Ibrutinib is intended to be used for the treatment of patients diagnosed with Waldenström's macroglobulinaemia (WM). Ibrutinib is an orally-active, small molecule, selective irreversible Bruton's tyrosine kinase (Btk). Ibrutinib irreversibly binds to Btk, thus inhibiting B-cell proliferation and survival through specific active-site occupancy. Ibrutinib is currently licensed in the EU for the treatment of chronic lymphocytic leukaemia and mantle-cell lymphoma. WM is relatively rare with just over 400 patients diagnosed in the UK each year. There is a male predominance and the incidence appears to be higher in those from White ethnic groups. The median survival for patients with WM is at least 7 years based on various reports; given that the median age of onset of 73 years and co-morbidities are common, it has been calculated that the disease-specific mortality is closer to 12 years. There is no single accepted treatment for WM. Patients only receive therapy if they have symptoms or signs related to WM and/or specific laboratory abnormalities. The main therapeutic options include chemotherapy with alkylating agents or nucleoside analogues, and biological therapy with rituximab, either alone or as part of combination regimens where studies are ongoing. Selected patients may also be suitable for high dose therapy with stem cell rescue. Ibrutinib is currently in one phase II clinical trial as monotherapy investigating its impact on overall response rates. Results from this trial are anticipated in 2016.
Details
Project Status: Completed
Year Published: 2015
URL for published report: http://www.hsric.nihr.ac.uk/topics/ibrutinib-imbruvica-for-waldenstroems-macroglobulinaemia/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Tyrosine Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • Waldenstrom Macroglobulinemia
Contact
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name: c.packer@bham.ac.uk
Contact Email: c.packer@bham.ac.uk
Copyright: NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.